Arrivent Biopharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Arrivent Biopharma Inc (AVBP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Arrivent Biopharma Inc vs Its Competitors
- Profitability: Its -806.3% net margin compares with 17.0% for the peer group.
- Scale: Arrivent Biopharma Inc ranks #170 of 543 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Arrivent Biopharma Inc accounted for 0.0% of combined revenue among its tracked peer group.
- Structure: Arrivent Biopharma Inc operates in the following segments: Single Reportable Segment.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AVBP Sales vs. its Competitors, Q3 2026
With a net margin of -806.26 %, Arrivent Biopharma Inc reported lower profitability than its competitors (17.03 %).
Arrivent Biopharma Inc generated 0.00 % of the combined sales of its peer group.
API endpoints for this dataset
Arrivent Biopharma Inc vs. its Competitors, Q3 2026
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Arrivent Biopharma Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Arrivent Biopharma Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Arrivent Biopharma inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Arrivent Biopharma Inc's competitor groups requires a Commercial License.
Arrivent Biopharma Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Arrivent Biopharma inc | - | - | - | No |
| Competitors combined (102) | ||||
| High-Confidence Competitors (5) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AVBP Stock Performance relative to its Competitors
AVBP Stock Performance relative to High-Confidence Competitors
AVBP Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 3 | Abcellera Biologics Inc | 282.9% | Outperformed |
| 4 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 5 | Xencor Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Arrivent Biopharma Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Arrivent Biopharma Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Arrivent Biopharma inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Arrivent Biopharma inc |
647.31 | - |
 Eli Lilly And Company |
1,278,223.12 | 86,462.00 |
 Johnson and Johnson |
694,227.07 | 99,335.00 |
 Abbvie Inc |
521,818.56 | 66,014.00 |
 Merck and Co Inc |
362,966.50 | 66,569.00 |
 Novartis Ag |
313,288.75 | 56,674.00 |
| SUBTOTAL | 5,104,900.72 | 856,088.48 |
Sign in to see all competitors of Arrivent Biopharma inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Arrivent Biopharma inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Arrivent Biopharma Inc's Competitors Named by the Company
Competitive relationships identified from Arrivent Biopharma Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Black Diamond Therapeutics, Inc. | Company report | 85% |
| Bayer AG | Company report | 85% |
| Dizal Pharmaceutical | Company report | 85% |
| Boehringer Ingelheim | Company report | 85% |
| Taiho Pharmaceutical Co., Ltd. | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| AstraZeneca | Company report | 85% |
| Cullinan Therapeutics, Inc. | Company report | 85% |
| Blossom Hill Therapeutics | Company report | 85% |
| Oric Pharmaceuticals | Company report | 85% |
Company report basis, confidence, active dates and source counts for Arrivent Biopharma Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Arrivent Biopharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Arrivent Biopharma inc | Single Reportable Segment 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Arrivent Biopharma inc .
Arrivent Biopharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Arrivent Biopharma inc | 647 | - | -2,195,714 |
| Eli Lilly And Company | 1,278,223 | 1,729,240 | 551,594 |
| Johnson and Johnson | 694,227 | 705,504 | 114,311 |
| Abbvie Inc | 521,819 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,967 | 887,587 | 42,267 |
| Novartis Ag | 313,289 | 752,973 | 185,566 |
| PEERS TOTAL | 5,104,253 | 920,539 | 127,886 |
Sign in to see all peers for Arrivent Biopharma inc .
Arrivent Biopharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Abbott Laboratories | Non-US 57.70 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Arrivent Biopharma inc .
Arrivent Biopharma Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 490 companies in Arrivent Biopharma Inc's industry classification, broader than the peer set above. Market cap in millions of $.Arrivent Biopharma Inc ranks #170 of 490 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 995, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,291,611 | 24.11 % |
| 2 | Johnson and Johnson | 689,109 | 12.86 % |
| 3 | Abbvie Inc | 525,845 | 9.81 % |
| 4 | Merck and Co Inc | 364,300 | 6.80 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 170 | Arrivent Biopharma inc | 632 | 0.01 % |
Market cap and industry share for the rest of Arrivent Biopharma Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-12.
Arrivent Biopharma Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 165 | Wave Life Sciences Ltd | 692 | -53.31 % |
| 166 | Kura Oncology Inc | 678 | -28.62 % |
| 167 | Design Therapeutics Inc | 665 | 37.05 % |
| 168 | Geron Corporation | 664 | -20.81 % |
| 169 | Shattuck Labs Inc | 1,234 | 12.3% |
| 170 | Arrivent Biopharma inc | 632 | -31.48 % |
| 171 | Aclaris Therapeutics Inc | 1,234 | 12.3% |
| 172 | Capricor Therapeutics inc | 1,234 | 12.3% |
| 173 | Monopar Therapeutics Inc | 1,234 | 12.3% |
| 174 | Sagimet Biosciences inc | 1,234 | 12.3% |
| 175 | Neurogene Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Arrivent Biopharma Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-12. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Arrivent Biopharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.3x | - |
| EV / EBITDA | - | 15.1x | - |
| P/B | 4.4x | 4.2x | +0.1x |
| Return on Equity | -48.60 % | industry aggregate | -70.84 % |
| Return on Invested Capital | -26.01 % | -9.73 % (avg) | -16.28 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Arrivent Biopharma Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Arrivent Biopharma Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Arrivent Biopharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 995 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Arrivent Biopharma Inc's dedicated Suppliers and Customers pages, not here.
Arrivent Biopharma Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Arrivent Biopharma Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Arrivent Biopharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 70.8 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (44.40 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Arrivent Biopharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Arrivent Biopharma inc | 3.68 | 14.61 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Sign in to see all peers for Arrivent Biopharma inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Arrivent Biopharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Arrivent Biopharma inc | Q3 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +10.1 % | +0.5 % |
Sign in to see all peers for Arrivent Biopharma inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Arrivent Biopharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Arrivent Biopharma inc | Q3 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Sign in to see all peers for Arrivent Biopharma inc .
Arrivent Biopharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Arrivent Biopharma inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
Sign in to see all peers for Arrivent Biopharma inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Arrivent Biopharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Arrivent Biopharma inc | - | - |
| Eli Lilly And Company | 46.45 | 14.78 |
| Johnson and Johnson | 42.89 | 6.99 |
| Abbvie Inc | 50.69 | 7.90 |
| Merck and Co Inc | 118.51 | 5.45 |
| Novartis Ag | 22.40 | 5.53 |
| PEERS AVERAGE | 42.98 | 5.96 |
Sign in to see all peers for Arrivent Biopharma inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.